PRO 155

Drug Profile

PRO 155

Alternative Names: PRO-155

Latest Information Update: 09 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Laboratorios Sophia
  • Class Eye disorder therapies; Nonsteroidal anti-inflammatories
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ocular inflammation

Most Recent Events

  • 01 Dec 2013 Phase-II clinical trials in Ocular inflammation in Mexico (Ophthalmic)
  • 03 Aug 2012 Laboratorios Sophia plans a phase II trial for Ocular inflammation in Mexico (NCT01657266)
  • 24 Feb 2012 Laboratorios Sophia completes enrolment in its phase I trial in Healthy volunteers in Mexico (NCT01535443)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top